Oncology outcomes

How big is the ovarian cancer burden in China, and where is it heading?

Wang Y, Wang Z, Zhang Z, et al. · Frontiers in public health · 2023

Open access · cc by · source: Europe PMC

GBD 2019 estimates show China’s ovarian cancer prevalence/incidence/mortality ASRs rose sharply since 1990, with ~196k cases in 2019 and projected faster growth than the global average to 2030.

Save to library View original Ask PaperFren Study this in NoteFren

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.

Inspect source passages

How big is the ovarian cancer burden in China, and where is it heading?

These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.

~196,000 cases; 45,000 new; 29,000 deaths in 2019.

In China, there were about 196,000 cases, 45,000 new cases and 29,000 deaths owing to OC in 2019.

ASR prevalence/incidence/mortality +105.98%/+79.19%/+58.93% since 1990.

The age-standardized rates (ASRs) of prevalence, incidence and mortality have increased by 105.98%, 79.19%, and 58.93% respectively by 1990.

Read passages in the original paper

Key findings

Large absolute burden in 2019; ASRs up ~106%/79%/59% for prevalence/incidence/mortality since 1990; acceleration 2016–2019; worse burden after age 40; high fasting glucose top risk, then high BMI.

Methodology

They pulled GBD 2019 OC metrics for China, analyzed age/year patterns with joinpoint and Bayesian age-period-cohort models, ranked risk factors, and projected burden through 2030.

Limitations

Modeled GBD estimates are not a primary registry census and projections depend on model assumptions.

Related papers in this topic

Same topic cluster — not a recommendation engine.